Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas.

Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found ...